Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.53 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.53 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.51 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13319977 | 1.00 | GRIA1 (0.53) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL6493867 | 1.00 | GRIA1 (0.53) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL1811917 | 1.00 | GRIA1 (0.53) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL3182737 | 1.00 | GRIA1 (0.53) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL8252920 | 0.90 | GRIA1 (0.42) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL2783303 | 0.85 | GRIA2 (0.64) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL20553364 | 0.85 | GRIA2 (0.64) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL8867563 | 0.85 | GRIA2 (0.64) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| Tezampanel Anhydrous SCHEMBL3688366 | 0.83 | GRIA1 (0.65) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| Tezampanel Anhydrous SCHEMBL3227089 | 0.83 | GRIA1 (0.65) | GRIA1GRIA2GRIA3GRIA4GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160257957-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM SPECTRUM DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-09-08 | — | — | US | claimed |
| US-20130225623-A1 | Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2013-08-29 | — | — | US | claimed |
| US-20130058915-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM SPECTRUM DISORDERS | Children's Medica Center Corporation (US) | 2013-03-07 | — | — | US | claimed |
| EP-2544688-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM SPECTRUM DISORDERS | President and Fellows of Harvard College (US) | 2013-01-16 | — | — | EP | claimed |
| WO-2011109398-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM SPECTRUM DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-09-09 | — | — | WO | claimed |
| WO-2011053636-A1 | METHODS OF TREATING PSYCHIATRIC OR NEUROLOGICAL DISORDERS WITH MGLUR ANTAGONISTS | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2011-05-05 | — | — | WO | claimed |
| US-20040192722-A1 | Selective iGluR5 receptor antagonists | FILLA SANDRA ANN (US) | 2004-09-30 | — | — | US | claimed |
| US-20040067978-A1 | Methods of treating disorders with Group I mGluR antagonists | BROWN UNIVERSITY RESEARCH FOUNDATION (BURF) (US) | 2004-04-08 | — | — | US | claimed |
| US-20030100539-A1 | Methods of treating neurological disorders with group I mGluR antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-29 | — | — | US | claimed |
| US-6242462-B1 | NOVEL DECAHYDROISOQUINOLINE DERIVATIVES WHICH ARE SELECTIVE GLUR5 RECEPTOR ANTAGONISTS. | ELI LILLY AND COMPANY | 2001-06-05 | — | — | US | claimed |
| WO-2023042888-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING COGNITIVE DECLINE OR FOR TREATING OVERWEIGHTNESS OR OBESITY | 国立大学法人 琉球大学 | 2023-03-23 | — | — | WO | disclosed |
| WO-2023042887-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING COGNITIVE DECLINE, EXCESS WEIGHT, OR OBESITY | 国立大学法人 琉球大学 | 2023-03-23 | — | — | WO | disclosed |
| US-20160257957-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM SPECTRUM DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-09-08 | — | — | US | disclosed |
| EP-2544688-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME | HARVARD COLLEGE (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20150359766-A1 | METHODS OF TREATING AUTISM WITH mGluR5 ANTAGONISTS | UNIV BROWN (US) | 2015-12-17 | — | — | US | disclosed |
| US-20040192722-A1 | Selective iGluR5 receptor antagonists | FILLA SANDRA ANN (US) | 2004-09-30 | — | — | US | disclosed |
| US-6759418-B2 | 6-(((2S)-2-(ALKOXYCABONYL)-4,4-DIFLUOROPYRROLIDINYL)METHYL)-1, 2, 3.4, 4A, 5, 6, 7, 8, 8A-DECAHYDROISOQUINOLINE-3-CARBOXYLATE, OR ACID DERIVATIVES, USEFUL FOR TREATING MIGRAINE, AND DURAL PROTEIN EXTRAVASATION | ELI LILLY AND COMPANY | 2004-07-06 | — | — | US | disclosed |
| US-20040067978-A1 | Methods of treating disorders with Group I mGluR antagonists | BROWN UNIVERSITY RESEARCH FOUNDATION (BURF) (US) | 2004-04-08 | — | — | US | disclosed |
| US-20030100539-A1 | Methods of treating neurological disorders with group I mGluR antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-29 | — | — | US | disclosed |
| US-6242462-B1 | NOVEL DECAHYDROISOQUINOLINE DERIVATIVES WHICH ARE SELECTIVE GLUR5 RECEPTOR ANTAGONISTS. | ELI LILLY AND COMPANY | 2001-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192722-A1 | Selective iGluR5 receptor antagonists | GRM5, GRIK5, GPR35 | GRIA1 44/4885GRIA2 35/4885GRIA3 24/4885 |
| US-20030100539-A1 | Methods of treating neurological disorders with group I mGluR antagonists | GRM5, GRIK5, GRIN1 | GRIA1 21/4885GRIA2 23/4885GRIA3 18/4885 |
| US-20150359766-A1 | METHODS OF TREATING AUTISM WITH mGluR5 ANTAGONISTS | GRM5, GRIK5, GRIK4 | GRIA1 26/4885GRIA2 23/4885GRIA3 18/4885 |
| US-20040067978-A1 | Methods of treating disorders with Group I mGluR antagonists | GRM5, GRIK5, GRM2 | GRIA1 15/4885GRIA2 18/4885GRIA3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.